Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apollomics Inc. - Class A Ordinary Shares
(NQ:
APLM
)
0.2055
+0.0140 (+7.31%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Apollomics Inc. - Class A Ordinary Shares
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2024
Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Presentation at the 2024 BIO International Convention
May 29, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Private Placement Financing and Addition to Board of Directors
May 08, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
April 25, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 10, 2024
Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR...
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 02, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
March 28, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
March 26, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
March 04, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
January 19, 2024
Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
January 17, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
January 03, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Present at the 2024 Biotech Showcase
January 02, 2024
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
December 04, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
November 29, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
November 28, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
November 16, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
October 31, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
October 26, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
October 23, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
October 16, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
September 28, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Apollomics Inc.
Via
GlobeNewswire
Apollomics Inc. (NASDAQ: APLM) Featured in Coverage of the Inaugural EF Hutton Global Conference
May 10, 2023
Via
Investor Brand Network
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
April 11, 2023
Dr. Redkar to discuss importance of HGF/cMET pathway, which can play critical role in origin of several cancers
From
Apollomics, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Apollomics Inc. (NASDAQ: APLM) Closes on Business Combination, Begins Trading
March 31, 2023
Via
Investor Brand Network
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.